Acute promyelocytic leukemia · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Arsenic trioxide monotherapy Variant #01 | — | R 39 096 | 60d | — | — | ~6 | ~R 234 574 indirect | — |
Busulfan and Melphalan Variant #01 | — | R 5 951 | — | — | — | ~1 | ~R 5 951 PFS proxy · indirect | 1 |
2 of 2 regimens shown